We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-8.9%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$525M
AUM Growth
-$493M
Cap. Flow
-$436M
Cap. Flow %
-83.03%
Top 10 Hldgs %
41.99%
Holding
85
New
22
Increased
4
Reduced
37
Closed
18
Avg Time Held Equity + Options
1.2 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
1.3 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$18.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.7M
3
COR icon
Cencora
COR
+$9.87M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$8.59M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.4M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$33.8M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$29.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$26.1M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$25.4M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 90.96%
2 Miscellaneous 9.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BSX icon
1
Boston Scientific
BSX
$64B
$33.9M 6.46%
336,000
-179,000
-35% -$18M
2022 Q1
12 quarters
DNTH icon
2
Dianthus Therapeutics
DNTH
$4.17B
$31.2M 5.95%
1,720,902
-1,152,098
-40% -$25.4M
2023 Q3
6 quarters
UNH icon
3
UnitedHealth
UNH
$365B
$26.4M 5.04%
50,500
-9,500
-16% -$4.86M
2024 Q3
2 quarters
CGON icon
4
CG Oncology
CGON
$5.48B
$24M 4.58%
980,942
-116,858
-11% -$3.29M
2024 Q1
4 quarters
HUM icon
5
Humana
HUM
$51.9B
$21.4M 4.08%
81,000
-8,200
-9% -$2.22M
2024 Q3
2 quarters
HUM icon
6
CALL
Humana
HUM
$51.9B
$21.2M 4.03%
+80,000
New +$21.6M
2025 Q1
0 quarters
NTRA icon
7
Natera
NTRA
$58.3B
$16.9M 3.21%
119,200
-104,600
-47% -$16.8M
2020 Q3
18 quarters
REGN icon
8
Regeneron Pharmaceuticals
REGN
$82B
$16.1M 3.07%
25,400
+17,000
+202% +$11.7M
2024 Q4
1 quarter
EXAS icon
9
DELISTED
Exact Sciences
EXAS
$15.3M 2.91%
353,000
-250,011
-41% -$12.7M
2024 Q2
3 quarters
BEAM icon
10
Beam Therapeutics
BEAM
$2.55B
$13.9M 2.64%
+709,517
New +$18.6M
2025 Q1
0 quarters
GKOS icon
11
Glaukos
GKOS
$9.77B
$13.2M 2.51%
134,000
-36,000
-21% -$4.8M
2024 Q1
4 quarters
DXCM icon
12
DexCom
DXCM
$33.1B
$12.3M 2.34%
180,000
-138,000
-43% -$11.3M
2024 Q1
4 quarters
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$1.5B
$11.7M 2.22%
322,100
-29,900
-8% -$1.24M
2021 Q3
14 quarters
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.22B
$11.4M 2.17%
925,000
-575,000
-38% -$8.11M
2020 Q2
19 quarters
COR icon
15
Cencora
COR
$65.2B
$10.9M 2.08%
+39,300
New +$9.87M
2025 Q1
0 quarters
JAZZ icon
16
Jazz Pharmaceuticals
JAZZ
$13.9B
$9.93M 1.89%
80,000
-154,500
-66% -$20.2M
2022 Q2
11 quarters
THC icon
17
Tenet Healthcare
THC
$22.2B
$9.68M 1.85%
72,000
-65,000
-47% -$8.56M
2022 Q4
9 quarters
NBIX icon
18
Neurocrine Biosciences
NBIX
$13.9B
$9.48M 1.81%
85,700
-134,700
-61% -$17.1M
2020 Q4
17 quarters
DHR icon
19
Danaher
DHR
$163B
$9.12M 1.74%
44,500
-22,500
-34% -$4.91M
2023 Q3
6 quarters
AXSM icon
20
Axsome Therapeutics
AXSM
$8.47B
$8.98M 1.71%
77,000
-111,000
-59% -$12.6M
2022 Q3
10 quarters
GMAB icon
21
CALL
Genmab
GMAB
$23.3B
$8.48M 1.62%
+433,100
New +$9.08M
2025 Q1
0 quarters
INSM icon
22
Insmed
INSM
$21.7B
$8.16M 1.56%
107,000
-125,800
-54% -$9.62M
2024 Q2
3 quarters
OGN icon
23
Organon & Co
OGN
$3.61B
$7.97M 1.52%
+535,000
New +$8.23M
2025 Q1
0 quarters
TMO icon
24
Thermo Fisher Scientific
TMO
$258B
$7.71M 1.47%
15,500
-29,100
-65% -$15.8M
2023 Q4
5 quarters
XENE icon
25
Xenon Pharmaceuticals
XENE
$3.32B
$7.68M 1.46%
229,000
-245,000
-52% -$9.3M
2023 Q2
7 quarters
1
2 3 4

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q1 2025 Portfolio in Review

As of Q1 2025, Avidity Partners Management held 85 positions worth $525M, down 48% from $1.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management withdrew a net $436M in Q1 2025, closing 18 positions and reducing 37 holdings. Its most notable exit was Intuitive Surgical, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Beam Therapeutics worth $13.9M.

  • Avidity Partners Management's largest Q1 2025 buy was Beam Therapeutics: 709,517 shares worth $13.9M.
  • Avidity Partners Management added most to Regeneron Pharmaceuticals in Q1 2025, an estimated $11.7M increase.
  • Avidity Partners Management's biggest Q1 2025 reduction was Mirum Pharmaceuticals, cutting an estimated $29.5M.
  • Avidity Partners Management fully exited Intuitive Surgical in Q1 2025, selling an estimated $33.8M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $525M portfolio in Q1 2025.
  • Avidity Partners Management opened 22 new positions and closed 18 in Q1 2025.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $525M.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.